Rubius Therapeutics reports $167.7M loss in 2020

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share. The clinical-stage biopharmaceutical company, which has built a manufacturing facility in Smithfield, reported a $163.5 million loss in 2019, or $2.08 per diluted share. The company is genetically engineering red blood cells to create an…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.